Clinical trials: Metabolic Evaluation
Fabry Disease
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
Fabry Disease is a rare blood disorder that some people are born with. People with Fabry disease have low levels of an enzyme called alpha-galactosidase A. This enzyme helps to cut down fat-like substances.
- Trial name
- NCT07187440
- Testing
- No intervention
- Where
- 18 sites in China
- Volunteers
- 200 people
- Sponsor
- Takeda
Type 1 Diabetes, Type 2 Diabetes
Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes
This study will collect sensor data in subjects with T1D or T2D, 2-80 years of age.
- Trial name
- NCT07864168
- Testing
- Next Generation Extended Wear Sensors
- Where
- 18 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
This study will evaluate whether the addition of sitagliptin reduces hemoglobin A1C (A1C) more than the addition of placebo for participants with type 2 diabetes mellitus (T2DM) on a steady dose of acarbose.
- Trial name
- NCT01177384
- Testing
- Sitagliptin phosphate, Acarbose, Glimepiride
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC
Dyslipidemia
A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)
This study will evaluate and compare the effectiveness of MK-0653 (Vytorin) to current standard treatment with other statins for the treatment of dyslipidemia in moderate, moderately-high and high-risk participants.
- Trial name
- VYCTORY (NCT01587235)
- Testing
- Ezetimibe/simvastatin, Other Statin
- Sponsor
- Organon and Co
Healthy
A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers
The purpose of this study is to evaluate the effect of canagliflozin on gastrointestinal glucose absorption in healthy volunteers.
- Trial name
- NCT01173549
- Testing
- no intervention
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypoglycemia
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
The purpose of this study is to demonstrate that G-Pen(TM) glucagon is comparable to Lilly Glucagon(TM) in terms of safety and efficacy, as a treatment for severe hypoglycemia, a complication of diabetes.
- Trial name
- NCT01972152
- Testing
- G-Pen(TM) 1 mg, Lilly Glucagon(TM) 1 mg, G-Pen(TM) 0.5 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Xeris Pharmaceuticals
Diabetes, Healthy
A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects
This trial is conducted in Europe. The aim of the trial is to evaluate the effect of semaglutide on cardiac repolarisation in healthy subjects.
- Trial name
- NCT02064348
- Testing
- semaglutide, moxifloxacin
- Where
- Germany
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose
The purpose of this study is to compare the relative bioavailability of JNJ-64565111 between subcutaneous (SC) administrations in the upper arm versus the abdomen, and between SC administrations in the thigh versus the abdomen in…
- Trial name
- NCT03586843
- Testing
- JNJ-64565111
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Drug Interaction
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport
This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
- Trial name
- NCT05334108
- Testing
- Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Emalex Biosciences Inc.
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.
- Trial name
- COURAGE-ALS (NCT04944784)
- Testing
- Reldesemtiv
- Where
- 84 sites in United States, Australia and 14 more
- Volunteers
- 489 people
- Sponsor
- Cytokinetics
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.
- Trial name
- ENDURE (NCT00856284)
- Testing
- Alogliptin, Metformin, Glipizide
- Where
- 261 sites in United States, Argentina and 30 more
- Volunteers
- 2,639 people
- Sponsor
- Takeda
AL Amyloidosis
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04512235
- Testing
- CAEL-101, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
- Where
- 110 sites in United States, Australia and 17 more
- Volunteers
- 281 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hypertension, Hypercholesterolemia
Clinical Trial to Evaluate the Efficacy and Safety of DP-R212
The purpose of this study is to determine superiority of DP-R212 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.
- Trial name
- NCT02955368
- Testing
- DP-R212, C1-R212, C2-R212
- Sponsor
- Alvogen Korea
PreDiabetes
Investigation of Nutrilite Glucose Health Herbal Drink on Prediabetes Persons
The goal of this two arms, randomized, double-blind controlled trial is to study whether Nutrilite herbal drink could ameliorate blood glucose level in prediabetes population.
- Trial name
- NCT07690735
- Testing
- Nutrilite Glucose health herbal drink
- Where
- China
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Amway (China) R&D Center
Diabetes Mellitus, Type 2
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects
This study is an open-label, randomized, fed, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-393 in healthy subjects
- Trial name
- NCT04260438
- Testing
- CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T, CKD-393 0.5/100/1000mg formulation 1 Tab. 1T, CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus
A User Performance and System Use Evaluation of a New Blood Glucose Monitoring System ( BGMS)
This study is the US Regulatory Clinical Evaluation - User Performance and System Use Evaluation of a new Blood Glucose Monitoring System (BGMS).
- Trial name
- NCT03851549
- Testing
- New BGMS (US)
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 360 people
- Sponsor
- LifeScan Scotland Ltd
Overweight, Obesity
Effect of Chili Pepper Extract on Weight and Fat Loss and Metabolism Increase
The purpose of this study is to test the safety and effectiveness of a purified extract of CH-19 Sweet, containing capsinoids.
- Trial name
- NCT00825838
- Testing
- Chronic consumption of chili pepper extract
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ajinomoto USA, INC.
Diabetes, Diabetes Mellitus, Type 2
An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice
This study is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy, safety and convenience of using repaglinide (NovoNorm®) in type 2 diabetes management in routine clinical practice.
- Trial name
- NCT01498900
- Testing
- repaglinide
- Where
- Turkey (Türkiye)
- Volunteers
- 30,554 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes
This study was designed to directly assess the effects of vildagliptin on gastric emptying in people with type 2 diabetes.
- Trial name
- NCT00351507
- Testing
- Vildagliptin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.